Ignite Creation Date:
2025-12-24 @ 11:51 AM
Ignite Modification Date:
2025-12-31 @ 6:24 AM
Study NCT ID:
NCT05782361
Status:
RECRUITING
Last Update Posted:
2025-08-20
First Post:
2023-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Sponsor:
Institute of Cancer Research, United Kingdom
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2028-03-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-01-09
Completion Date Type:
ESTIMATED
First Submit Date:
2023-01-13
First Submit QC Date:
None
Study First Post Date:
2023-03-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-15
Last Update Post Date:
2025-08-20
Last Update Post Date Type:
ACTUAL